Fig. 7
From: 3D organoid-derived human glomeruli for personalised podocyte disease modelling and drug screening
Toxicity screening using cultured organoid glomeruli. a MAFB-BFP2 OrgGloms can be cultured in isolation in a 96-well format. Live imaging of glomeruli at 48 h post-treatment with doxorubicin showed a dose-dependent decrease of BFP2-reporter intensity. b Fixed glomeruli immunolabelled with Caspase-3 showed activation of this pro-apoptotic pathway following doxorubicin treatment. Scale bar 100 µm. c Semi-quantitative analysis of BFP2-reporter intensity (blue) alongside OrgGlom diameter (red) showed a dose-dependent reduction in both glomerular diameter and BFP2-reporter intensity. One-way ANOVA p < 0.0001; error bars = SEM; significant difference between sequential doses assessed by Tukey’s multiple comparisons test. BFP2-reporter intensity: F-value = 80.3; DF = 5; biological replicates n = 16 per dose. OrgGlom Diameter: F-value = 60.94; DF = 5; biological replicates n = 16 per dose
